Patents by Inventor Masaki Daini
Masaki Daini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357220Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).Type: ApplicationFiled: May 20, 2021Publication date: November 9, 2023Inventors: Tomoaki HASUI, Satoshi MIKAMI, JR., Toru YAMASHITA, Shinji NAKAMURA, Shinji MORIMOTO, Toshihiro IMAEDA, Kazuaki TAKAMI, Masaki DAINI, Hiroyuki KAKEI, Minoru NAKAMURA, Fumie YAMAGUCHI, Chunxiang WANG, Sachie TAKASHIMA, Makoto KAMATA, Yuya OGURO, Shuhei IKEDA
-
Publication number: 20230348435Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).Type: ApplicationFiled: May 20, 2021Publication date: November 2, 2023Inventors: Tomoaki HASUI, Satoshi MIKAMI, Toru YAMASHITA, Shinji NAKAMURA, Shinji MORIMOTO, Toshihiro IMAEDA, Kazuaki TAKAMI, Masaki DAINI, Hiroyuki KAKEI, Minoru NAKAMURA, Fumie YAMAGUCHI, Chunxiang WANG, Sachie TAKASHIMA, Shogo HASHIZUME
-
Patent number: 11702419Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 15, 2021Date of Patent: July 18, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Patent number: 11459325Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: January 30, 2019Date of Patent: October 4, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
-
Publication number: 20220289679Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 15, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Publication number: 20220274982Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 1, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Patent number: 11319286Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: August 2, 2018Date of Patent: May 3, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
-
Publication number: 20220089525Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: January 23, 2020Publication date: March 24, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yuya OGURO, Makoto KAMATA, Satoshi MIKAMI, Shinji MORIMOTO, Sachie TAKASHIMA, Masaki DAINI, Osamu KUBO, Fumiaki KIKUCHI, Akinori TOITA, Florian PUENNER, Takahito KASAHARA, Masataka MURAKAMI, Shuhei IKEDA, Fumie YAMAGUCHI, Minoru NAKAMURA, Takafumi YUKAWA
-
Publication number: 20210332053Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: March 15, 2021Publication date: October 28, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
-
Patent number: 11059780Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: March 7, 2018Date of Patent: July 13, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaki Daini, Yuhei Miyanohana, Satoshi Mikami, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
-
Publication number: 20210179603Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: February 16, 2021Publication date: June 17, 2021Inventors: Shigemitsu MATSUMOTO, Yasushi HATTORI, Masashi TOYOFUKU, Shinji MORIMOTO, Masaki DAINI, Takuto KOJIMA, Tomohiro KAKU, Mitsuhiro ITO
-
Patent number: 11034700Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: March 7, 2018Date of Patent: June 15, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Satoshi Mikami, Masaki Daini, Yuhei Miyanohana, Hideo Suzuki, Kenichiro Shimokawa, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
-
Patent number: 10968213Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: June 27, 2019Date of Patent: April 6, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Publication number: 20210087186Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: January 30, 2019Publication date: March 25, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Tomohiro OHASHI, Zenichi IKEDA, Yuta TANAKA, Florian PÜNNER, Takeshi YAMAMOTO, Keiko KAKEGAWA, Fumiaki KIKUCHI, Nao MORISHITA, Takahito KASAHARA, Masaki SETO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Satoshi MIKAMI, Minoru SASAKI
-
Publication number: 20200392149Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: March 7, 2018Publication date: December 17, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Satoshi MIKAMI, Masaki DAINI, Yuhei MIYANOHANA, Hideo SUZUKI, Kenichiro SHIMOKAWA, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
-
Publication number: 20200385346Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: August 2, 2018Publication date: December 10, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
-
Publication number: 20200385345Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: March 7, 2018Publication date: December 10, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Masaki DAINI, Yuhei MIYANOHANA, Satoshi MIKAMI, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
-
Patent number: 10807987Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 27, 2019Date of Patent: October 20, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Publication number: 20200207734Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: August 2, 2018Publication date: July 2, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
-
Publication number: 20200017444Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: September 20, 2019Publication date: January 16, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA